Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Joseph Drabick

Hematology | Oncology
PennState Health
The Milton S Hershey Medical Center Physicians Group
500 University Dr, 
Hershey, PA 
Clinical Trials:Currently Recruiting for 1 Trial

Distinguished in WT1-Related Wilms Tumor Syndromes
PennState Health
The Milton S Hershey Medical Center Physicians Group
500 University Dr, 
Hershey, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Drabick is a Hematologist and an Oncologist in Hershey, Pennsylvania. Dr. Drabick is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Melanoma, Adult Soft Tissue Sarcoma, Fibrosarcoma, Tissue Biopsy, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 70 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in PA
Hospital Affiliations
Milton S Hershey Medical Center
Penn State Health Holy Spirit Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

THE MILTON S HERSHEY MEDICAL CENTER PHYSICIANS GROUP
500 University Dr, Hershey, PA 17033
Call: 717-531-8202

Additional Areas of Focus

Dr. Drabick has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


11 Clinical Trials

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
Enrollment Status: Recruiting
Publish Date: January 24, 2025
Intervention Type: Biological
Study Drugs: RP1, Nivolumab
Study Phase: Phase 2
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Biological
Study Drugs: Bevacizumab, Ipilimumab
Study Phase: Phase 2
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Other, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drug: APG-115+Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase Ib/II Study of Propranolol With Fixed-Dose Pembrolizumab in Patients With Unresectable Stage III and Stage IV Melanoma
A Phase Ib/II Study of Propranolol With Fixed-Dose Pembrolizumab in Patients With Unresectable Stage III and Stage IV Melanoma
Enrollment Status: Suspended
Publish Date: July 02, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Pembrolizumab, Propranolol Hydrochloride
Study Phase: Phase 1/Phase 2
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drugs: Pazopanib, Pazopanib Hydrochloride, Sapanisertib
Study Phase: Phase 1/Phase 2
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001)
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001)
Enrollment Status: Terminated
Publish Date: August 03, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of the Concomitant Administration of Indoximod Plus Immune Checkpoint Inhibitors for Adult Patients With Advanced or Metastatic Melanoma
A Phase 1/2 Study of the Concomitant Administration of Indoximod Plus Immune Checkpoint Inhibitors for Adult Patients With Advanced or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: June 05, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Enrollment Status: Completed
Publish Date: June 13, 2019
View 10 Less Clinical Trials

70 Total Publications

Angelica gigas Nakai (Korean Dang-gui) Root Alcoholic Extracts in Health Promotion and Disease Therapy - active Phytochemicals and In Vivo Molecular Targets.
Angelica gigas Nakai (Korean Dang-gui) Root Alcoholic Extracts in Health Promotion and Disease Therapy - active Phytochemicals and In Vivo Molecular Targets.
Journal: Pharmaceutical research
Published: September 20, 2024
View All 70 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Megan S. Wheelden
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Megan S. Wheelden
Hematology Oncology | Hematology | Oncology

The Milton S Hershey Medical Center Physicians Group

500 University Dr, 
Hershey, PA 
 (0.1 miles away)
717-531-8202
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Megan Wheelden is a Hematologist Oncology specialist and a Hematologist in Hershey, Pennsylvania. Dr. Wheelden is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Muscle Invasive Bladder Cancer, and Bone Marrow Aspiration.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Monika D. Joshi
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Monika D. Joshi
Hematology Oncology | Hematology | Oncology

The Milton S Hershey Medical Center Physicians Group

500 University Dr, 
Hershey, PA 
 (0.1 miles away)
717-531-8395
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Monika Joshi is a Hematologist Oncology specialist and a Hematologist in Hershey, Pennsylvania. Dr. Joshi is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Renal Cell Carcinoma (RCC), and Bone Marrow Aspiration.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sunil Saroha
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sunil Saroha
Hematology | Oncology

Abramson Cancer Center Kennett Square

400 McFarlan Road, Suite 300, 
Kennett Square, PA 
 (59.2 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sunil Saroha is a Hematologist and an Oncologist in Kennett Square, Pennsylvania. Dr. Saroha is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Idiopathic Neutropenia, and Thrombocytopenia. Dr. Saroha is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Drabick's expertise for a condition
ConditionClose
  • Elite
  • Melanoma
    Dr. Drabick is
    Elite
    . Learn about Melanoma.
    See more Melanoma experts
  • Distinguished
  • Adult Soft Tissue Sarcoma
    Dr. Drabick is
    Distinguished
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Alveolar Soft Part Sarcoma
    Dr. Drabick is
    Distinguished
    . Learn about Alveolar Soft Part Sarcoma.
    See more Alveolar Soft Part Sarcoma experts
  • Bone Tumor
    Dr. Drabick is
    Distinguished
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Clear Cell Sarcoma
    Dr. Drabick is
    Distinguished
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Fibrosarcoma
    Dr. Drabick is
    Distinguished
    . Learn about Fibrosarcoma.
    See more Fibrosarcoma experts
  • Rhabdoid Tumor
    Dr. Drabick is
    Distinguished
    . Learn about Rhabdoid Tumor.
    See more Rhabdoid Tumor experts
View All 8 Distinguished Conditions
  • Advanced
  • Acute Myeloid Leukemia (AML)
    Dr. Drabick is
    Advanced
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Adrenal Cancer
    Dr. Drabick is
    Advanced
    . Learn about Adrenal Cancer.
    See more Adrenal Cancer experts
  • Adrenocortical Carcinoma
    Dr. Drabick is
    Advanced
    . Learn about Adrenocortical Carcinoma.
    See more Adrenocortical Carcinoma experts
  • Angiosarcoma of the Scalp
    Dr. Drabick is
    Advanced
    . Learn about Angiosarcoma of the Scalp.
    See more Angiosarcoma of the Scalp experts
  • Bladder Cancer
    Dr. Drabick is
    Advanced
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Chromophobe Renal Cell Carcinoma
    Dr. Drabick is
    Advanced
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
View All 33 Advanced Conditions
  • Experienced
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Drabick is
    Experienced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Drabick is
    Experienced
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myelomonocytic Leukemia
    Dr. Drabick is
    Experienced
    . Learn about Acute Myelomonocytic Leukemia.
    See more Acute Myelomonocytic Leukemia experts
  • Agranulocytosis
    Dr. Drabick is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Drabick is
    Experienced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Anal Cancer
    Dr. Drabick is
    Experienced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
View All 61 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved